8-K: Dianthus Claseprubart Shines in Phase 2 gMG Trial

Dianthus Therapeutics announced positive top-line data from its Phase 2 MaGic trial for claseprubart (DNTH103) in generalized Myasthenia Gravis, demonstrating significant efficacy and a favorable safety profile.

Summary

• Claseprubart (DNTH103) achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13 for both 300mg and 600mg Q2W doses.
• A rapid and sustained onset of action was observed, with statistically significant improvements in MG-ADL and QMG scores as early as Week 1.
• The 300mg Q2W dose also showed statistical significance and clinical meaningfulness across other key efficacy endpoints, including Minimal Symptom Expression (MSE), Myasthenia Gravis Composite (MGC) Score, and the Myasthenia Gravis Quality of Life Scale (MG-QoL-15r).
• Claseprubart demonstrated a favorable safety profile with no related serious infections, clinical symptoms of emergent autoimmune disease, or drug-related serious adverse events or discontinuations.
• The company plans to initiate a Phase 3 gMG trial in 2026, evaluating both 300mg Q2W and 300mg Q4W doses versus placebo, following an end-of-Phase 2 meeting with the FDA.

Sentiment

Score: 9

Explanation: The filing reports highly positive top-line Phase 2 clinical trial data for a key pipeline asset, demonstrating strong efficacy and a favorable safety profile. This significantly de-risks the asset and supports its potential as a best-in-class treatment, which is a major value driver for a clinical-stage biotechnology company. The planned progression to Phase 3 and the robust cash runway further enhance the positive outlook.

Positives

• Both 300mg and 600mg Q2W doses of claseprubart achieved statistically significant and clinically meaningful improvements in MG-ADL and QMG scores at Week 13.
• Rapid onset of action was observed, with statistically significant improvements in MG-ADL and QMG scores as early as Week 1 for both doses.
• The 300mg Q2W dose showed statistically significant improvements across all five key efficacy measures: MG-ADL (placebo-adjusted -1.8 points, P=0.0113), QMG (placebo-adjusted -2.4 points, P=0.0144), MSE (23% vs placebo, P=0.0550), MGC (placebo-adjusted -5.6 points, P=0.0008), and MG-QoL-15r (placebo-adjusted -2.2 points, P=0.0414).
• Claseprubart exhibited a favorable safety profile, comparable to placebo, with no drug-related serious adverse events, no related serious bacterial infections, and no discontinuations due to related adverse events.
• The comparable efficacy and safety across both doses support the target product profile of a single, convenient 300mg/2mL self-administered, subcutaneous autoinjector dosed once every two weeks, without the need for a Boxed Warning or REMS for meningococcal infections.
• The company maintains a strong balance sheet with approximately $309 million in cash, cash equivalents, and investments as of June 30, 2025, providing a cash runway into the second half of 2027.

Negatives

• While generally well tolerated, the 600mg Q2W dose arm showed a higher incidence of newly positive anti-nuclear antibodies (ANA) at 36.4% compared to 5.9% in the 300mg arm and 0% in the placebo arm, although no clinical symptoms of autoimmune activation were observed.

Risks

• Preclinical testing and clinical trial data for claseprubart may not be predictive of the results or success of ongoing or later clinical trials.
• The development of claseprubart or other company compounds may take longer and/or cost more than planned.
• The company may be unable to successfully complete the clinical development of its compounds.
• There is a risk of delays in initiating, enrolling, or completing planned clinical trials.
• Company compounds may not receive regulatory approval or become commercially successful products.

Future Outlook

The company plans to initiate a Phase 3 gMG trial for claseprubart in 2026, investigating both 300mg Q2W and 300mg Q4W doses versus placebo, pending regulatory feedback. The year 2026 is expected to be catalyst-rich, with the gMG Phase 3 trial initiation, interim responder analysis from the Phase 3 CAPTIVATE trial in CIDP in 2H26, and top-line results from the Phase 2 MoMeNtum trial in MMN in 2H26. Claseprubart is positioned as a potential best-in-class, first-line biologic treatment for neuromuscular diseases.

Management Comments

• "The results from MaGic mark a significant milestone for Dianthus and are an important step forward for people living with gMG. These results are also a reflection of the commitment and talent of the entire Dianthus team, and I want to thank them for their outstanding execution of this clinical trial." Marino Garcia, President and Chief Executive Officer.
• "The concordance of the efficacy and safety data from the MaGic trial strongly support our best-in-class target product profile for claseprubart 300mg/2mL Q2W in gMG and bolsters our confidence in our execution of the CIDP and MMN clinical programs." Marino Garcia, President and Chief Executive Officer.
• "The consistent and meaningful treatment effect seen in both treatment arms across multiple standard MG efficacy metrics in this Phase 2 trial gives me and my team great confidence in our ability to execute a successful Phase 3 trial." Simrat Randhawa, MD, Chief Medical Officer.
• "If these impressive results were replicated in a Phase 3 trial, claseprubart may be a differentiated treatment option for patients with gMG." Dr. Tuan Vu, Professor of Neurology at the University of South Florida Morsani College of Medicine.

Industry Context

The announcement positions claseprubart as a potential first-line biologic in the multibillion-dollar U.S. gMG market, which currently has over 100,000 patients, with less than 20% of AChR+ patients treated with biologics. Dianthus aims to address unmet needs by combining the efficacy of C5 complement inhibitors, the safety profile of C1s inhibitors, and the convenience of self-administered autoinjectors like Dupixent, potentially expanding the market for patient-friendly treatment options. The company is also building a neuromuscular franchise with claseprubart for CIDP and MMN, targeting large patient populations.

Comparison to Industry Standards

• Claseprubart's target product profile aims for comparable efficacy to C5 complement inhibitors, targeting a 1.6-2.1-point improvement versus placebo on MG-ADL, similar to observed improvements for Soliris (-1.9 points), Ultomiris (-1.6 points), and Zilbrysq (-2.1 points) in their respective Phase 3 trials (Note: cross-trial comparisons cannot be made due to differences in trial design and patient populations).
• The safety profile is targeted to be comparable to FDA-approved C1s and Classical Pathway inhibitors like Enjaymo, aiming for no Boxed Warning or REMS, by selectively inhibiting the classical complement pathway while preserving lectin and alternative pathways.
• Convenience is benchmarked against Dupixent, targeting a one-click, self-administered 300mg/2mL subcutaneous autoinjector for Q2W or Q4W dosing, which is faster and less burdensome than current IV or high-volume SC C5 and FcRn biologics.
• In QMG score, claseprubart 300mg Q2W achieved a placebo-adjusted improvement of -2.4 points, and 600mg Q2W achieved -2.5 points, which compares favorably to Ultomiris's -2.0 points in its Phase 3 CHAMPION-MG trial (Note: cross-trial comparisons cannot be made).

Stakeholder Impact

• Shareholders: Highly positive clinical trial results are likely to significantly increase investor confidence and potentially lead to a substantial increase in share price, reflecting the de-risking of a key pipeline asset and its market potential.
• Patients with gMG: The positive data suggests a promising new treatment option that could offer superior efficacy, a more favorable safety profile, and greater convenience (self-administered, infrequent dosing) compared to existing therapies, addressing significant unmet needs.
• Employees: Successful clinical trial outcomes validate the company's research and development efforts, boosting morale and potentially attracting new talent.
• Regulatory Authorities: The positive Phase 2 data will be a key input for discussions with the FDA regarding the design of the Phase 3 trial, potentially streamlining the path to approval if subsequent trials are successful.

Next Steps

• Host an end-of-Phase 2 meeting with the FDA to align on the proposed design for a Phase 3 trial for claseprubart in gMG.
• Initiate the Phase 3 gMG trial in 2026, evaluating both 300mg Q2W and 300mg Q4W doses vs. placebo.
• Anticipate results from the interim responder analysis of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 2026.
• Anticipate top-line results from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) in the second half of 2026.

Key Dates

Recommendation

The positive top-line Phase 2 results for claseprubart in gMG are a significant de-risking event for Dianthus Therapeutics. The drug demonstrated statistically significant and clinically meaningful improvements across multiple key efficacy endpoints, coupled with a favorable safety profile, supporting its potential 'best-in-class' status. The planned progression to a Phase 3 trial in 2026, along with a robust cash runway into 2H27 and a pipeline-in-a-product strategy for other neuromuscular diseases, positions the company for substantial future growth. Given the large unmet need in the gMG market and the differentiated profile of claseprubart, this announcement significantly enhances the company's long-term value proposition, making it a strong buy for investors.

Keywords

Claseprubart, DNTH103, Myasthenia Gravis, gMG, Phase 2 MaGic trial, Autoimmune disease, Complement therapeutics, Biotechnology, Clinical trial results, Neuromuscular franchise, AChR+, MG-ADL, QMG, C1s inhibitor